Fundraising Fox
The Column Group
Venture capitalActively deployingSan Francisco · Pre-Seed–Late Stage · 45 people tracked
Also known as Column Capital Advisors, Llc · THE COLUMN GROUP MANAGEMENT LP
Find your way into The Column Group
Each arrow is one introduction. Sign up to fill in the first one.
Ask Badreddin Edris to introduce you to Peter Svennilson
You →Badreddin · together at The Column Group →Peter
Ask Jamie Chen to introduce you to Leon Chen
You →Jamie · together at The Column Group →Leon
Ask Sam Okafor to introduce you to Tim Kutzkey
You →Sam · together at The Column Group →Tim
- Jeff Goater520 people can intro you
- Sarah Hymowitz111 people can intro you
- Hui Tian103 people can intro you
Sign up to find every way you can get introduced to The Column Group
- Your email: who you already know at The Column Group, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the The Column Group team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
TCG is a life sciences venture firm employing an edge-to-edge investment model centered primarily on company formation while maintaining the capital to provide long-term private and public support. Its ecosystem spans multiple complementary vehicles — TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil and TCG Crossover (TCGX) — that together advance technology platforms, single assets and later-stage programs from inception through exit. Rooted in fundamental science, the firm takes a hands-on approach, partnering closely with founders, recruiting leadership talent, and mentoring CEOs. Across roughly two decades it has started and invested in 55 companies, backing advances in biology, chemistry and technology to develop therapeutic breakthroughs.
Source: firm website, verified Sep 29, 2026.
Team · 45 people
from the firm's website & public directories
Founder mafia
5 people who came through The Column Group went on to found or lead other companies.
What they invest in
from 58 of 64 portfolio companiesBiotech ×53Healthtech ×35Deep Tech ×18Medical Devices ×16AI & Machine Learning ×10Digital Health ×8Circular Economy ×1Cleantech ×1
HQs:United States×42Brazil×1Croatia×1New Zealand×1
Who they back
founder profiles across 23 portfolio companiesFounding team size:solo founder×122 founders×63 founders×34+ founders×2
Where their founders studiedfrom 19 founders with education data
University of California, Berkeley ×3Harvard Medical School ×2Stanford University ×2The Johns Hopkins University School of Medicine ×2University of Michigan ×2
What their founders studiedfrom 18 founders with field-of-study data
Life Sciences ×11Medicine ×7Chemistry ×2Computer Science ×2
Where their founders worked beforefrom 18 founders with career history
Atlas Venture ×3Flexus Biosciences ×2Gladstone Institutes ×2Nextech Invest ×2
backed the same founder in 2+ companies: 3 founders
Investments · 64 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 32024 · 72023 · 42022 · 22021 · 52020 · 32017 · 22016 · 22015 · 52014 · 12013 · 143 dated
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Edward Mead JohnsonJames Wood JohnsonRobert Wood Johnson IJoaquin DuatoinJ. Duato(Chief Executive Officer)
Co-investorsAisling CapitalAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESvenBio Partners
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Nextech InvestTaiho Ventures, LLCViking GlobalOrbiMed
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical DevicesRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Co-investorsBain Capital Life SciencesForesite CapitalGen CapitalGV (Google Ventures)Illinois VenturesNextech Invest+2 more
Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.
BiotechHealthtechSouth San Francisco, US
Deepak Srivastava, M.D.(Scientific Founder)inEric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)inSheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in
Co-investorsGV (Google Ventures)RA CapitalvenBio Partners
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Board seatJeff Goater· per SEC Form D
Co-investorsAtlas VentureForesite CapitalARCH Venture PartnersAlexandriaDecheng Capital
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)in
Co-investorsLux CapitalRA CapitalNextech Invest
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)inAmanda J. Redig(Chief Medical Officer)inScott Lesley(President & CSO)inPamela Holland(SVP of Biology)inSally Johnson(Chief People Officer)in
Co-investorsMRL Ventures FundVida Ventures
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)inWilliam Ho
Co-investorsAtlas VentureDigitalis VenturesDroia VenturesYK Bioventures
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsSamsara BioCapitalSanofi Ventures
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US
C. Alexander Kamb(Director)inJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Board seatDavid V. Goeddel· per SEC Form D
Co-investorsNextech InvestVida VenturesSamsara BioCapital
Carmot is a clinical-stage biotechnology company developing novel treatments for obesity and type 2 diabetes through biased receptor agonist compounds.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesBerkeley, US
Daniel A. Erlanson(Executive Officer, Director)Stig K. Hansen(Executive Officer, Director)
BoardAetna Wun Trombley(Director)
Board seatPeter SvennilsonTim KutzkeyTim KutzkeyLarry Lasky· per SEC Form D
Co-investorsFrazier Life SciencesHorizons VenturesRA CapitalTCG Crossover
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Board seatJohn JoseyJames EvangelistaPeter Svennilson· per SEC Form D
Co-investorsBerkeley CatalystHemisphere Ventures LLCJude GomilaLifeforce CapitalMission Bay CapitalMission Biocapital+3 more
Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)
Board seatPeter SvennilsonDavid V. Goeddel· per SEC Form D
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThird Rock Ventures
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inDaniel Becker(Director)
Board seatJohn Josey· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersViking GlobalAccess IndustriesRA Capital
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)inMaureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Board seatDavid V. Goeddel· per SEC Form D
Co-investorsATEL VenturesB3 HoldingNextech InvestSoftBank Vision Fund8VCCasdin Capital+1 more
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)
BoardTerry McGuire(Director)inJoshua Wolfe(Director)in
Board seatTim Kutzkey· per SEC Form D
Co-investorsDns CapitalIllumina VenturesLux CapitalPolaris PartnersTwo Sigma Ventures
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Board seatPeter SvennilsonTim KutzkeyDavid V. Goeddel· per SEC Form D
Co-investorsBerkeley FrontierIaso VenturesViking GlobalYsios CapitalAlexandriaFidelity Investments+8 more
NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway.
BiotechHealthtechSouth San Francisco, US
Diana Peng Bockus(Executive Officer, Director)
BoardRoger M. Perlmutter(Director)
Board seatPeter SvennilsonTim Kutzkey· per SEC Form D
Co-investorsRho Ventures
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)
BoardDavid Goeddel(Director)inMark Goldsmith(Director)
Board seatDavid V. Goeddel· per SEC Form D
Co-investorsBain Capital Life SciencesEcoR1 CapitalForesite CapitalSofinnova VenturesWellington ManagementThird Rock Ventures
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Board seatJeff Goater· per SEC Form D
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieDeerfield Management CompanyJJDC+4 more
Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardDavid Goeddel(Director)inCraig Parker(Executive Officer, Director)
Board seatDavid V. GoeddelTim Kutzkey· per SEC Form D
Co-investors5AM VenturesAccess BiotechnologyHorizons Ventures
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)AbbVieJJDC+3 more
Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.
BiotechHealthtech
Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRichard Markus(Chief Medical Officer)inCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalGV (Google Ventures)+4 more
Tau provides formal verification of compiled binaries by generating mathematical proofs of correctness or identifying bugs, addressing risks from AI-assisted code generation and complex software systems.
AI & Machine LearningCybersecurityDeveloper ToolsEnterprise SoftwareSan Francisco, US
Pedro Nobre(Founder)inLuke Johnston(Founder)in
Co-investorsY CombinatorBlast.ClubFounders FactoryLux CapitalUnpopular Ventures
Cajal Therapeutics develops novel therapies through translating scientific advances into treatments for patients.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesSeattle, US
Andrew Dervan(Co-Founder and Co-Chief Executive Officer)inIan Peikon(Co-Founder and Co-Chief Executive Officer)inRob Hershberg(Co-Founder and Executive Chairman)in
Co-investorsLux CapitalDolby Family Ventures
Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.
BiotechSouth San Francisco, US
Susan M. Molineaux(Executive Officer, Director)inWilliam Waddill(Executive Officer)in
BoardJean M. George(Director)Deepa Pakianathan(Director)inRalph E. Christoffersen(Director)Jonathan Drachman(Director)
Co-investorsLongwood FundVenture Capital Investment Management
Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.
BiotechDeep TechHealthtechBoston, US
Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in
Co-investorsAstellas Venture Management LLCThird Rock VenturesEisai Innovation, Inc.Ono Venture Investment, Inc.
Pioneering a drug discovery method based on tracking the movement of individual proteins in living cells.
Co-investorsEcoR1 CapitalHorizons VenturesLux CapitalTCG CrossoverGeneral CatalystInnovation Endeavors
.png)
Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesAbingworth+3 more
Creating cancer therapeutics through novel immunology insights; acquired by Bristol-Myers Squibb in April 2015 for $1.3B.
BiotechSan Carlos, US
Juan Carlos Jaen(Executive Officer, Director)inTerry Rosen(Executive Officer, Director)inLuis Bayol(Executive Officer)in
BoardBeth Seidenberg(Director)inDave Goeddel(Director)William Rieflin(Director)
Co-investorsKleiner Perkins
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more
Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.
BiotechHealthtechSan Carlos, US
Andrew Allen(Executive Officer, Director)inVassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)inWayne(CEO)Rachel(VP of Operations)Shefali Agarwal(Director)
Co-investorsFrazier Life SciencesGV (Google Ventures)Sofinnova VenturesREDMILEVersant Ventures
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsBay City CapitalGV (Google Ventures)LAVLilly Asia VenturesAlexandriaFrazier Healthcare Partners+1 more
Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.
BiotechHealthtechMedical DevicesSeattle, US
David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in
Co-investorsAisling CapitalAtlas VentureHM Venture PartnersOUP (Osage University Partners)Sanderling VenturesSanofi Ventures+4 more
Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
BiotechDeep TechHealthtechMedical Devices
Howard Federoff(Scientific Co-Founder, Chief Medical Officer and Executive Vice President of Corporate Medicine and Science)in
Co-investorsCure Ventures
Kimia is a therapeutics company developing new drugs through its ATLAS platform, working with partners in the pharmaceutical and biotechnology industries.
AI & Machine LearningBiotechDeep Tech
Stig Hansen(Founder)in
Co-investorsAirTree VenturesHorizons VenturesBlackbird VenturesDIMENSIONDimension CapitalSkip Capital
Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers.
BiotechDeep TechHealthtechSouth San Francisco, US
NILO develops technology to upcycle hard-to-recycle plastic waste, primarily polyethylene (PE) and polypropylene (PP), into materials for use in circular systems and safer products.
Circular EconomyCleantechNew Materials
Co-investorsArc AngelsIcehouse VenturesPacific Channel
Nilo Saúde provides AI agents and automation solutions designed for healthcare institutions to improve operational efficiency and financial outcomes.
AI & Machine LearningDigital HealthHealthtech
Co-investorsCitrino VenturesIKJ CapitalMAYA Capital VenturesTau VenturesVox CapitalThe Fund
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechNew York, US
Jeff Goater(Executive Officer, Director)inKim Seth(CEO)in
BoardTim Kutzkey(Executive Officer, Director, Promoter)in
Co-investorsDCVC (Data Collective)AlexandriaDCVC BioLux Capital
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsCurative VenturesForesite CapitalNextech InvestRidgeback CapitalVida Ventures
The Faculty of Pharmacy and Biochemistry offers pharmacy and biochemistry degree programs, including a Pharmacy programme in English aligned with EU Directive 2005/36/EC for EU/EEA registration.
EdTech
Co-investorsVesna AdvisorsNextech InvestRA Capital
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoinMichael Martin(President, Chief Executive Officer)inStephen Mullennix(Executive Officer)in
BoardSerge Messerlian(Director)inCariad Chester(Director)in
Co-investorsaMoonCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesPivotal Life Sciences+3 more
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.
BiotechHealthtech
Co-investorsForesite CapitalFrazier Life SciencesGV (Google Ventures)Kleiner PerkinsMedicxiSolasta Ventures+1 more
Genentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
AI & Machine LearningBiotechDigital HealthSouth San Francisco, US
Co-investorsAisling CapitalKleiner PerkinsNew Enterprise Associates (NEA)
Constellation Pharmaceuticals was a Cambridge, MA clinical-stage biopharmaceutical company developing epigenetics-based cancer therapies, including BET and EZH2 inhibitors.
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesExSight VenturesLongitude CapitalTachyon Ventures
Monimoit develops cancer therapeutics by combining chemical proteomics, covalent-based molecular technologies, and patient-derived translational insights to target difficult-to-drug cancer-promoting proteins and overcome resistance to existing treatments.
BiotechDeep Tech
SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists.
AI & Machine LearningBiotechDeep Tech
Maria Soloveychik(PhD)in
Co-investorsNorth South VenturesOMX Ventures8VC
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsAN Venture PartnersCure Ventures
Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.
BiotechHealthtechCambridge, US
Hui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)
BoardKarin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)
Co-investorsMRL Ventures FundSR One Capital Management
Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need.
BiotechDeep TechHealthtechMedical Devices
David(Co-Founder)Maria Grazia Roncarolo(Co-Founder, President and Head of R&D)
Co-investorsNeva Sgr.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exonics TherapeuticsFLX BioIgenica BiotherapeuticsNgm BiopharmaceuticalsRYNE Biotechnology Inc.Site Tx, Inc.Aragon PharmaceuticalsBE BiopharmaCleave TherapeuticsKenai TherapeuticsSmall MoleculesTr1x
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 12
4 IPOs · 8 acquisitions · showing 9Johnson & JohnsonNYSE: JNJORIC PharmaceuticalsNASDAQ: ORICRevolution MedicinesNASDAQ: RVMDTenaya TherapeuticsNASDAQ: TNYAConstellation Pharmaacq. by NovartisNgm Biopharmaceuticalsacq. by The Column GroupPeloton Therapeuticsacq. by MerckRAPT Therapeuticsacq. by GSKThumbnail for Constellation Pharmaceuticalsacq. by MorphoSys
Portfolio news
latest coverage across their companiesNura Bio · finsmes.com · Jun 22, 2026
Tr1X Bio · tr1x.bio · Feb 24, 2026
Cajal · ycombinator.com · Feb 24, 2026
Nilo Therapeutics · finsmes.com · Oct 9, 2025
Fund performance · per public LP disclosures · 6
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| The Column Group Fund Opportunity Fund IIILPs: Employees' Retirement System of Rhode Island, Carnegie Corporation of New York | 2022 | — | 0.2% | 1.01x | 0.34x |
| The Column Group Fund VLPs: Employees' Retirement System of Rhode Island, Carnegie Corporation of New York | 2022 | — | -19.1% | 0.77x | 0.00x |
| Column Group IVLPs: The Regents of the University of California | 2019 | — | -1.8% | 0.95x | 0.07x |
| Column Group IIILPs: The Regents of the University of California | 2016 | — | 7.7% | 1.25x | 0.78x |
| Column Group IILPs: The Regents of the University of California | 2014 | — | 7.8% | 2.40x | 1.88x |
| The Column Group, L.P.LPs: The Regents of the University of California | 2005 | — | 23.4% | 2.10x | 0.79x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Tenaya Therapeutics | 23.9% | $15.00 | Jul 2021 | $141M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has The Column Group made?
- The Column Group has 64 tracked investments, 12 of which have exited, including 6 dated in the last 24 months.
- What stage does The Column Group invest at?
- The Column Group invests at the Pre-Seed, Seed, Series A, Series B, Growth, Late Stage stages.
- What is The Column Group's typical check size?
- The Column Group typically writes checks of $30M.
- What sectors does The Column Group focus on?
- The Column Group focuses on Biotech, Deep Tech, Longevity.
- Where is The Column Group located?
- The Column Group is headquartered in San Francisco, US.
- Does The Column Group lead rounds?
- The Column Group typically participates in rounds rather than leading them.
- Who does The Column Group co-invest with?
- The Column Group most often shares deals with Nextech Invest, Foresite Capital, GV (Google Ventures), among 86 tracked co-investors.
- What size deals does The Column Group back?
- Across 22 deals with disclosed amounts, The Column Group has joined rounds of $2M – $150M (median $57.5M).
Images
Co-investors · 38
Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
▶26 more co-investors
Third Rock VenturesSamsara BioCapitalCure Ventures8VCTwo Sigma VenturesVersant VenturesSanofi VenturesVida VenturesDCVC (Data Collective)Canaan PartnersARCH Venture PartnersLeaps by BayerGeneral CatalystInnovation EndeavorsDimension CapitalSR One Capital ManagementPivotal Life SciencesAstellas Venture Management LLCFounders FundUS Venture PartnersGeneral AtlanticM12 (Microsoft's Venture Fund)MPM BioImpactPfizer Venture InvestmentsOmega FundsLightstone Ventures
Firms observed investing alongside The Column Group, from public investor directories. Shared companies are the overlap with The Column Group's recorded portfolio.
Similar investors
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Pontifax is a venture capital firm focused on life sciences and healthcare technologies, investing across all development stages from early-stage startups to clinical-stage growth companies.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Fundamental Ventures is an early-stage venture firm that writes first checks into founders removing fundamental constraints that hold back human progress, spanning hard tech, deep science, and workflow innovation.